Alvotech Feed

	Est. tid*
2025-11-12	-	Kvartalsrapport 2025-Q3
2025-08-14	-	Kvartalsrapport 2025-Q2
2025-06-26	-	X-dag ordinarie utdelning ALVO 0.00 ISK
2025-06-25	-	Årsstämma
2025-05-08	-	Kvartalsrapport 2025-Q1
2025-03-26	-	Bokslutskommuniké 2024
2024-11-14	-	Kvartalsrapport 2024-Q3
2024-08-16	-	Kvartalsrapport 2024-Q2
2024-05-22	-	Kvartalsrapport 2024-Q1
2024-03-20	-	Bokslutskommuniké 2023
2023-11-14	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-06-06	-	Årsstämma
2023-05-19	-	Kvartalsrapport 2023-Q1

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

2025-11-12 22:40:00 Alvotech kynnir uppgjör fyrstu níu mánaða ársins 2025 og helstu áfanga í rekstri félagsins

2025-11-12 22:40:00 Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

2025-11-10 10:00:00 UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-10 10:00:00 Alvotech vinnur sigur í mikilvægu dómsmáli um framleiðslu og markaðssetningu AVT06 hliðstæðunnar við Eylea (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-10 10:00:00 UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-06 15:07:23 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA 660,00 ISK | +3,77% | 47,1 MISK

2025-11-06 15:00:00 Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu við Simponi (golimumab) 660,00 ISK | +3,77% | 47,1 MISK

2025-11-06 15:00:00 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA 660,00 ISK | +3,77% | 47,1 MISK

2025-11-04 22:01:00 Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update 636,00 ISK | -0,62% | 23,4 MISK

2025-11-04 22:01:00 Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk. 636,00 ISK | -0,62% | 23,4 MISK

2025-11-02 23:12:42 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 680,00 ISK | -28,42% | 147 MISK

2025-11-02 23:10:00 Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05 í Bandaríkjunum 680,00 ISK | -28,42% | 147 MISK

2025-11-02 23:10:00 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 680,00 ISK | -28,42% | 147 MISK

2025-10-22 11:00:40 Alvotech Announces Changes in Global Business Development and Commercial Operations Team 1010,00 ISK | -0,98% | 4,87 MISK

2025-10-22 11:00:00 Skipulagsbreytingar á viðskiptasviði Alvotech 1010,00 ISK | -0,98% | 4,87 MISK

2025-10-22 11:00:00 Alvotech Announces Changes in Global Business Development and Commercial Operations Team 1010,00 ISK | -0,98% | 4,87 MISK

2025-10-06 10:40:00 Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir fyrirhugaða hliðstæðu Alvotech við líftæknilyfið Xolair 1020,00 ISK | +0,99% | 1,54 MISK

2025-10-06 10:40:00 European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency 1020,00 ISK | +0,99% | 1,54 MISK

2025-09-22 12:15:00 Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva 968,00 ISK | +0,41% | 4,29 MISK

2025-09-22 12:15:00 European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva® 968,00 ISK | +0,41% | 4,29 MISK

2025-09-22 10:30:00 Lyfjastofnun Evrópu mælir með leyfi til markaðssetningar á Gobivaz, fyrirhugaðri hliðstæðu Alvotech við líftæknilyfið Simponi (golimumab) 968,00 ISK | +0,41% | 4,29 MISK

2025-09-22 10:30:00 European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner 968,00 ISK | +0,41% | 4,29 MISK

2025-09-19 13:45:00 Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður frá Alvotech 964,00 ISK | -0,62% | 12,2 MISK

2025-09-19 13:45:00 Alvotech Announces Marketing Approval in Japan of Three New Biosimilars 964,00 ISK | -0,62% | 12,2 MISK

2025-09-04 15:15:00 Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York 992,00 ISK | -0,60% | 13,3 MISK

2025-09-04 15:15:00 Alvotech tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley í New York 992,00 ISK | -0,60% | 13,3 MISK

2025-09-04 15:15:00 Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York 992,00 ISK | -0,60% | 13,3 MISK

2025-08-21 10:30:00 Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® 1020,00 ISK | -0,49% | 28,6 MISK

2025-08-21 10:30:00 Alvotech hlýtur leyfi til markaðssetningar í Evrópu á hliðstæðu við augnlyfið Eylea 1020,00 ISK | -0,49% | 28,6 MISK

2025-08-21 10:30:00 Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® 1020,00 ISK | -0,49% | 28,6 MISK

2025-08-20 12:05:00 Alvotech utser Patrik Ling till VP of Investor Relations Scandinavia 1025,00 ISK | -4,21% | 23,0 MISK

2025-08-20 12:05:00 Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia 1025,00 ISK | -4,21% | 23,0 MISK

2025-08-13 22:15:00 Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update 1005,00 ISK | -7,80% | 69,1 MISK

2025-08-13 22:15:00 Alvotech birtir uppgjör fyrir fyrstu sex mánuði ársins og kynnir nýjustu áfanga í rekstri félagsins 1005,00 ISK | -7,80% | 69,1 MISK

2025-08-13 22:15:00 Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update 1005,00 ISK | -7,80% | 69,1 MISK

2025-08-06 14:00:00 Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT 1060,00 ISK | -2,75% | 232 MISK

2025-08-06 14:00:00 Inbjudan til Alvotech presentation av bokslutskommunikén och rapporten för första halvåret 2025 1060,00 ISK | -2,75% | 232 MISK

2025-08-06 14:00:00 Alvotech kynnir uppgjör fyrri helmings ársins 2025 þann 14. ágúst nk. kl. 12 á hádegi 1060,00 ISK | -2,75% | 232 MISK

2025-08-06 14:00:00 Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT 1060,00 ISK | -2,75% | 232 MISK

2025-07-10 10:40:00 Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer 1065,00 ISK | -1,84% | 104 MISK

2025-07-10 10:40:00 Alvotech skipar Lindu Jónsdóttur í stöðu framkvæmdastjóra fjármálasviðs 1065,00 ISK | -1,84% | 104 MISK

2025-07-10 10:40:00 Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer 1065,00 ISK | -1,84% | 104 MISK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Alvotech

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden